Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights
Author: Vandana Singh | August 23, 2021 09:08am
Pfizer Inc (NYSE:PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ:TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion.
The offer price represents a 118% premium to the 60-day weighted average price for Trillium.
Trillium's portfolio includes biologics include immuno-oncology product candidates.
Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, emerging as a key immune checkpoint in hematological malignancies.
TTI-622 and TTI-621 are SIRPα-Fc fusion proteins currently in Phase 1b/2 development across several indications, focusing on hematological malignancies.